Russia faces shortage of anticancer drug Ixempra

27 January 2024

Russia has faced a shortage of another important anticancer drug - Ixempra (ixabepilone), which is designed for the treatment of breast cancer, reports The Pharma Letter’s local correspondent.

Over the past two years, the drug's right holder - the American subsidiary of the Russian drugmaker R-Pharm - has launched only one series of the drug into the Russian market. The company explains that due to a change in the distributor of the active ingredient, the drug has become more expensive. In this regard, R-Pharm hopes for an increase of the maximum price of the drug in order to resume supplies.

R-Pharm US acquired  rights to the drug from US pharma major Bristol-Myers Squibb (NYSE: BMY) in 2015. There are no analogues of Ixempra in Russia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical